Gene Therapy Payment Models Pose Multi-Year Budget Challenge for Payers

Gene therapies for rare diseases create structural tension between one-time treatments with multi-decade outcomes and payer systems built on annual budgets and short-term evidence cycles. With 26 FDA-approved gene therapies now in use and more coming, the piece argues healthcare delivery infrastructure and financing models—not just clinical science—will determine patient access and long-term sustainability. For Medicaid MCOs, this raises questions about payment structures, coverage decisions, and evidence generation obligations for high-cost, one-time interventions.

Pharmacy · Managed Care · Finance

This is outside commentary from Avalere, not part of Medicaid Monitor's independently scored news coverage.

More from Avalere